Blocking the HMGB1/TLRs/NF-κB pathway by lycorine to alleviate LPS-induced lung injury from inflammation and oxidative stress gave a new perspective for acute lung injury (ALI) therapy to be harnessed clinically. Here, HMGB1 is linked to acute lung injury.